APOC3 and diabetes mellitus: However, the findings from the large-scale phase III PROMINENT trial indicated that for individuals with high TG and diabetes, pemafibrate did not result in a decreased risk of cardiovascular events or mortality even though it led to a reduction of approximately 20–30% each in TG, RC, VLDL-C, and apoCIII [43].